
Pacific Biosciences of California, Inc.
PACBNASDAQHealthcareMedical - Devices
Regular session
$1.2901
−$0.0599 · -4.44%
PACB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
57
Fair Value
Momentum
48
Neutral
Sentiment
43
Mixed
Risk resilience
23
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websitePacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Mark Van Oene
- Listed since
- Oct 27, 2010
- Employees
- 485
Market position
Day range
Current $1.2901
52-week range
Current $1.2901
- Open
- $1.35
- Previous close
- $1.35
- Volume
- 929.25K
- 0.14× average
- Average volume
- 6.5M
- Average daily volume
- Market cap
- 400.71M USD
- Beta
- 2.32
- Market reference 1
- 50-day average
- $1.3982
- -7.73% below average
- 200-day average
- $1.6553
- -22.06% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -3×
- P/B (TTM)
- -12.07×
- P/S (TTM)
- 2.52×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 35.97%
- Operating margin
- -102.05%
- Net margin
- -82.49%
Financial health
- Debt / equity
- -21.26×
- Altman Z-score
- -4.71
- Piotroski F-score
- 2 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 160.01M USD | 154.01M USD | 200.52M USD | 128.3M USD | 130.51M USD |
| Cost of goods sold | 109.33M USD | 116.73M USD | 147.74M USD | 79.27M USD | 71.65M USD |
| Gross profit | 50.67M USD | 37.28M USD | 52.78M USD | 49.04M USD | 58.86M USD |
| Research and development | 97.31M USD | 134.92M USD | 187.17M USD | 193M USD | 112.9M USD |
| Selling, general, and administrative | 141.49M USD | 175.02M USD | 169.82M USD | 160.85M USD | 124.12M USD |
| Operating expenses | 608.24M USD | 511.6M USD | 387.25M USD | 356.23M USD | 269.3M USD |
| Interest expense | 6.95M USD | 13.41M USD | 14.34M USD | 14.69M USD | 12.53M USD |
| Depreciation and amortization | 504.91M USD | 53.35M USD | 32.69M USD | 17.32M USD | 11.59M USD |
| Operating income | −557.56M USD | −474.31M USD | −334.47M USD | −307.2M USD | −210.44M USD |
| Net income | −546.38M USD | −309.85M USD | −306.74M USD | −314.25M USD | −181.22M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -1.82
- FY2025
- Latest fiscal-year revenue
- 160.01M USD
- FY2025 · +3.89% year over year
- Next fiscal-year EPS consensus
- -0.453
- FY2026 · 3 analysts
- Next fiscal-year revenue consensus
- 158.27M USD
- FY2026 · 4 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
PACB news
PACB peers
ETFs holding PACB
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK17.02M0.26%5.56B USD0.75%$84.46-2.02%
ARK Genomic Revolution ETFARKG14.94M0.72%1.56B USD0.75%$47.87-3.20%
Vanguard Morningstar Total Stock Market ETFVTI13.35M0.00%2.3T USD0.03%$376.71-0.40%
iShares Russell 2000 ETFIWM9.72M0.01%81.62B USD0.19%$298.57-0.46%
Vanguard Extended Market ETFVXF5.02M0.01%93.7B USD0.05%$243.73-0.73%
iShares Russell 2000 Growth ETFIWO3.33M0.02%15.16B USD0.24%$383.13-1.09%
iShares Biotechnology ETFIBB2.9M0.03%10.75B USD0.44%$210.73-1.33%
Vanguard Russell 2000 ETFVTWO2.21M0.01%17.4B USD0.06%$120.71-0.45%
ARK Innovation ETFARKK- Market value
- 17.02M
- Weight
- 0.26%
- AUM
- 5.56B USD
- Expense ratio
- 0.75%
- Price / 1D
- $84.46-2.02%
ARK Genomic Revolution ETFARKG- Market value
- 14.94M
- Weight
- 0.72%
- AUM
- 1.56B USD
- Expense ratio
- 0.75%
- Price / 1D
- $47.87-3.20%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 13.35M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $376.71-0.40%
iShares Russell 2000 ETFIWM- Market value
- 9.72M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $298.57-0.46%
Vanguard Extended Market ETFVXF- Market value
- 5.02M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.73-0.73%
iShares Russell 2000 Growth ETFIWO- Market value
- 3.33M
- Weight
- 0.02%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $383.13-1.09%
iShares Biotechnology ETFIBB- Market value
- 2.9M
- Weight
- 0.03%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $210.73-1.33%
Vanguard Russell 2000 ETFVTWO- Market value
- 2.21M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $120.71-0.45%
Continue in GoAI
Research PACBresearch.disclaimer











